GlassScriptPhysician profile
Poorav Jitendra Patel
NPI 1689014409
$10,428.61
in general payments reported to CMS, 2019-2025
21 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,801 · 2020: $685 · 2021: $849 · 2022: $608 · 2023: $632 · 2024: $854 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277 · Consulting Fee: $1,170 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.25 |
| Consulting Fee | $1,170.00 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,692.68 | 2019-2020 | |
| Alcon Vision LLC | $2,200.17 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Glaukos Corporation | $2,129.12 | 2020-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Idose |
| Johnson & Johnson Surgical Vision, INC. | $1,865.89 | 2019-2025 | Tecnis Iol, Veritas Vision System, Lipiflow System Activator (Disposable) |
| Sight Sciences, INC. | $360.62 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $225.82 | 2020-2021 | |
| New World Medical,INC. | $148.98 | 2022-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Novartis Pharmaceuticals Corporation | $125.86 | 2019 | |
| Allergan, INC. | $125.00 | 2020 | |
| Rxsight INC | $116.64 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Genentech, INC. | $93.39 | 2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $75.57 | 2023 | Eylea, Eylea Hd |
| Horizon Therapeutics Plc | $58.17 | 2023 | Tepezza |
| Merz Pharmaceuticals, LLC | $40.09 | 2022 | |
| Genentech USA, INC. | $37.89 | 2023 | Vabysmo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $30.57 | 2023-2024 | Cequa |
| Carl Zeiss Meditec USA, INC. | $28.03 | 2024 | |
| Aerie Pharmaceuticals, INC. | $24.65 | 2020 | |
| Amgen INC. | $19.13 | 2024 | Tepezza |
| Bausch & Lomb Americas INC. | $16.50 | 2024 | Xiidra, Miebo |
| Omeros Corporation | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poorav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.